Stay updated with breaking news from Erick Fair. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
If you visit a local sports field on any Saturday morning this fall, you’re likely to see groups of children in brightly colored uniforms, participating in recreational youth soccer.
24.03.2022 - - Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 in Phase 1/2 study - - Favorable safety profile observed in initial dose cohort of BPX-603 in HER2+ solid ...
Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603 HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enrollment and apheresis of the first patient in the Phase 1/2 clinical trial for BPX-603 in patients with tumors that express human epidermal growth factor 2 (HER2). BPX-603 is Bellicum’s first dual switch GoCAR-T ® product candidate that incorporates the company’s iMC activation and CaspaCIDe ® safety switch technologies. “Initi...